早期转移性结直肠癌的生存结果:一个多中心匹配对分析
Bernhard Doleschal1, Dora Niedersüß-Beke2, Patrick Kirchweger3,4,5
1Department of Internal Medicine I for Hematology with Stem Cell Transplantation, Hemostaseology, and Medical Oncology, Ordensklinikum Linz, Linz, Austria.
Oncology
|September 12, 2023
概括
与老年患者相比,转移性结直肠癌 (mCRC) 的年轻患者的生存率有所改善,并接受更多的治疗线路. 这项研究表明,早期发病的mCRC患者从治疗中显著受益,挑战了以前的假设.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 临床研究 临床研究
背景情况:
- 转移性结直肠癌 (mCRC) 的存活率有所改善,主要受益于50岁以上的患者.
- 50岁以下患者的结肠直肠癌发病率和死亡率正在上升.
- 对较年轻的mCRC患者的治疗益处仍在调查中.
研究的目的:
- 为了比较50岁及以下的mCRC患者之间的临床结果.
- 评估早期结直肠癌 (eo-CRC) 与常规结直肠癌 (ro-CRC) 的治疗疗效.
主要方法:
- 对1077名mCRC患者 (2005-2019) 的回顾性分析.
- 患者分为eo-CRC (<50岁) 和ro-CRC (>50岁) 的类别.
- 倾向性得分匹配用于控制偏见并比较生存率.
主要成果:
- eo-CRC患者有不同的瘤特征,包括侧面性.
- 年轻的患者接受了更多的转移切除,并接受了更多的息治疗线路.
- 在eO-CRC患者中,即使经过统计调整,总体存活率也更高.
结论:
- 与老年患者相比,患有mCRC的年轻患者至少同等,如果不是更大,则从治疗中受益.
- 这些发现表明,仅仅年龄不应该排除对mCRC的积极治疗.
相关概念视频
Cancer Survival Analysis
381
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
381
Comparing the Survival Analysis of Two or More Groups
220
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
220
Kaplan-Meier Approach
178
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
178


